Shorter individuals twice as likely to develop esophageal cancer
the ONA take:
According to a new study published in the journal Clinical Gastroenterology and Hepatology, researchers at Fred Hutchinson Cancer Research Center in Seattle, Washington, have found that taller individuals are less likely to develop Barrett's esophagus and esophageal cancer than shorter individuals.
For the study, the researchers analyzed data from 14 studies within the International Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). They found that those in the lowest quartile of height, or men under 5'7" and women under 5'2", were approximately twice as likely as those in the highest quartile of height, or men taller than 6' and women taller than 5'5", to have esophageal cancer or Barrett's esophagus.
Bases on analyses, results were consistent among various other factors, including age, body mass index, education, gastroesophageal reflux disease (GERD) symptoms, sex, and smoking. Researchers suggest that height may be able to be used as a risk factors to identify patients with a higher risk of developing Barrett's esophagus or esophageal cancer. Of note, the relationship between height and esophageal cancer observed in this study is the opposite of what has been observed in breast, colorectal, and prostate cancers.
Taller individuals are less likely to develop Barrett's esophagus and esophageal cancer.
A new study has observed that tall people are less likely to suffer from esophageal cancer as compared to short people.
The study conducted a large pooled analysis using data from 14 population-based epidemiologic studies within the International Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), including 1,000 cases of esophageal cancer and twice as many cases of Barrett's esophagus, and twice as many controls.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
- Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|